Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ONC201 in Advanced Solid Tumors
NCT02250781Phase 1Completed
- Sponsor
- Rutgers University
- Start
- Jan 2015
- Primary completion
- Oct 2018
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dordaviprone in solid tumor, sponsored by Rutgers University. Primary endpoint: Dose limiting toxicity rate at Day 21. Started Jan 2015; status: completed.
02
Drugs
dordaviprone
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02250781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02250781.